Aurora Cannabis (NYSE: ACB) reports extension of exclusive supply with Luxembourg

Aurora Cannabis Inc (NYSE: ACB) announced on Thursday that the Luxembourg Health Ministry is the European subsidiary Aurora Deutschland, the exclusive provider of a national national supply of medical cannabis.

Aurora won the rights by bidding to sell to Luxembourg's de la Pharmacie et des Medicaments division.

This order is Aurora's second from the Luxembourg government. While there is little in quantity, management considers it validating.

Why it's important

"Add the many achievements of our European team, which also includes our new lineup as one of the three companies to establish domestic production in Germany, our Extended Delivery Agreement with Luxembourg strengthens Auror's ability to To act as a reliable partner that can easily meet the complex needs of various international markets, "Neil Belot, Aurora Chief Global Business Development Officer, said in a press release.

The agreement also strengthens the Aurora global dynasty.

"As the established European market leader, Aurora is exceptionally well positioned to leverage our significant early mover advantage to meet the growth of new medical cannabis markets as opportunities arise," said Maximilian Weinberg, Assistant Director of Aurora EU Business Development, said in the release.

Aurora's stock ended Wednesday at $ 8.59 per share and tr Options Trader Makes $ 239K Bearish Bet on Aurora Cannabis in Front of Profits